Dyne Therapeutics Inc (NASDAQ: DYN) on Monday, soared 6.11% from the previous trading day, before settling in for the closing price of $7.04. Within the past 52 weeks, DYN’s price has moved between $6.36 and $47.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -5.63%. With a float of $87.33 million, this company’s outstanding shares have now reached $102.32 million.
In an organization with 191 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Dyne Therapeutics Inc (DYN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dyne Therapeutics Inc is 22.80%, while institutional ownership is 80.95%. The most recent insider transaction that took place on Mar 13 ’25, was worth 1,733. In this transaction Chief Commercial Officer of this company sold 143 shares at a rate of $12.12, taking the stock ownership to the 96,057 shares. Before that another transaction happened on Mar 11 ’25, when Company’s SVP, Head of Finance & Admin. sold 1,343 for $11.38, making the entire transaction worth $15,283. This insider now owns 122,330 shares in total.
Dyne Therapeutics Inc (DYN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.20% during the next five years compared to -59.45% drop over the previous five years of trading.
Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators
Dyne Therapeutics Inc (DYN) is currently performing well based on its current performance indicators. A quick ratio of 15.60 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.35, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Dyne Therapeutics Inc (DYN)
Let’s dig in a bit further. During the last 5-days, its volume was 3.03 million. That was better than the volume of 2.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.27%. Additionally, its Average True Range was 0.93.
During the past 100 days, Dyne Therapeutics Inc’s (DYN) raw stochastic average was set at 4.45%, which indicates a significant decrease from 19.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 117.00% in the past 14 days, which was higher than the 91.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.02, while its 200-day Moving Average is $27.25. However, in the short run, Dyne Therapeutics Inc’s stock first resistance to watch stands at $7.66. Second resistance stands at $7.86. The third major resistance level sits at $8.18. If the price goes on to break the first support level at $7.14, it is likely to go to the next support level at $6.82. The third support level lies at $6.62 if the price breaches the second support level.
Dyne Therapeutics Inc (NASDAQ: DYN) Key Stats
Market capitalization of the company is 845.02 million based on 113,121K outstanding shares. Right now, sales total 0 K and income totals -317,420 K. The company made 0 K in profit during its latest quarter, and -89,540 K in sales during its previous quarter.
